18129-Lung Cancer-NA-445

Lung Cancer

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Address

3550 N E Loop 286
Paris, TX 75460
P: (903) 785-0031

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.